Vadodara: Alembic Pharma has announced that Sudhakar Pandiyan has been appointed as Head - Technical Operations (Sterile & ...

The competition in follicular lymphoma is rapidly intensifying, with three CAR-T therapies and three bispecific antibodies now approved for relapsed or refractory patients. As both classes of ...

Novartis India Limited (NIL) is a subsidiary of Swiss giant Novartis the world's second largest pharmaceutical company was incorporated on 13 December 1947. The Company is focused on manufacturing and ...

Tris Pharma, Inc. (Tris) has announced the promotion of Manesh Naidu, MBA, to chief commercial officer. Naidu previously ...

The US-based Gilead Sciences’ long-acting injectable HIV drug lenacapavir is at the centre of a patent opposition case ...

Novartis India Ltd. key Products/Revenue Segments include Pharmaceuticals, Commission and Sale of services for the year ending 31-Mar-2024.For the quarter ended 30-06-2024, the company has reported a ...

Intel secured up to $3.5 billion in federal subsidies to manufacture semiconductors for the U.S. Department of Defense. This ...

An FDA approval has officially lifted the curtain on a blockbuster market showdown between Novartis and Eli Lilly in early breast cancer. The FDA has greenlighted Novartis’ Kisqali, used in ...

Milan Jaros / Bloomberg via Getty Images Novartis said its Kisqali breast cancer drug produced longer success for those with certain forms of the disease. The drug maker reported Kisqali along ...

Kisqali, a key targeted therapy for breast cancer from Novartis, until now has been indicated only for patients with metastatic disease. But on Tuesday, the Food and Drug Administration approved ...

Novartis AG’s breast cancer drug helped prevent the disease coming back a year after treatment had ended, in new data that will be closely compared with a rival product from Eli Lilly. Novartis ...